top of page

Press Release: CTB-1 is now under FDA review!

Aug 2, 2023

1 min read

Updated: Jan 24, 2024

Additional updates coming soon...

Recent Posts

Advancing Cancer Immunotherapy: CTD-1

Advancing Cancer Immunotherapy: CTD-1

GTS Biotech Receives Rare Pediatric Disease Designation from the FDA for CTB-1

GTS Biotech Receives Rare Pediatric Disease Designation from the FDA for CTB-1

FDA Grants Orphan Drug Designation to GTS Biotech’s CTB-1 as a Treatment for Osteosarcoma

FDA Grants Orphan Drug Designation to GTS Biotech’s CTB-1 as a Treatment for Osteosarcoma

bottom of page